Tata Institute develops Rs 100 tablet to prevent cancer recurrence

This discovery comes after 10 long years of dedicated hardwork and also reduces the side effects of treatments like radiation and chemotherapy

Tata Institute, the renowned centre for cancer research and treatment has made a groundbreaking discovery. They have announced the creation of a Rs 100 tablet which can be used to prevent cancer recurrence. This discovery comes after 10 long years of dedicated hardwork and also reduces the side effects of treatments like radiation and chemotherapy.

Speaking to NDTV, Dr Rajendra Badve, a senior cancer surgeon at Tata Memorial Hospital, who was part of the research group, said, “Human cancer cells were inserted in rats for the research, which formed a tumour in them. The rats were then treated with radiation therapy, chemotherapy and surgery. It was found that when these cancer cells die, they break into tiny pieces called Chromatin particles. These particles can travel to other parts of the body through the bloodstream and when they enter healthy cells, they can turn them cancerous.”

The Tata Memorial Service said in its research that, dying cancer cells release cell-free chromatin particles (cfChPs, or fragments of chromosomes) which can turn healthy cells into cancerous ones. Some of the cfChPs may fuse with healthy chromosomes and cause new tumours.

“To find a solution to this problem, doctors gave pro-oxidant tablets with resveratrol and copper (R+Cu) to the rats,” Dr Badve told NDTV. The R+Cu generate Oxygen radicals, which destroy Chromatin Particles.

The ‘R+Cu’ when taken orally will generate oxygen radicals in the stomach which are quickly absorbed to enter blood circulation. The oxygen radicals destroy cfChPs released in circulation and prevent ‘Metastases’, which is the movement of cancer cells from one part of the body to another. The researchers also claimed that R+Cu prevents Chemotherapy toxicity.

“Tata doctors were working on this tablet for almost a decade. The tablet is awaiting approval from the Food Safety and Standards Authority of India (FSSAI). TIFR scientists have applied to FSSAI to approve this tablet. After getting the approval, it will be available in the market from June-July. This tablet will help to a great extent in improving cancer treatment,” the senior cancer surgeon said.

“While the budget for the treatment ranges from lakhs to crores, this tablet will be available everywhere for just ₹ 100,” he said.

The doctor said, “The effect on side-effects were tested on both rats and humans, but the prevention test was done only on rats. It will take about five years to complete the human trials for this. There were challenges during the research, many felt it was a waste of time and money. But today, everyone is happy and excited. It is a big success.”

You might also be interested in – Russia is close to developing cancer vaccines, claims President Putin

Related Articles

Back to top button